Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
18 hedge funds and large institutions have $2.5M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
171% more capital invested
Capital invested by funds: $924K → $2.5M (+$1.58M)
13% more funds holding
Funds holding: 16 → 18 (+2)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.54M |
| 2 |
AI
Atom Investors
Austin,
Texas
|
+$59.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.63K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$560 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$6.16K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.76K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.63K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.46K |
| 5 |
BlackRock
New York
|
-$112 |
ELOX Hedge Fund Activity: Q3 2023 in Review
18 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2023, worth a combined $2.5M — up 171% from $924K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ELOX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.54M. The largest seller was Clal Insurance, cutting an estimated $6.16K.
- 18 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2023, up from 16 in Q2 2023.
- Funds reported $2.5M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2023, up 171% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Armistice Capital, an estimated $1.54M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was Clal Insurance, an estimated $6.16K sold.
Based on aggregated 13F filings for Q3 2023.